Eikon Takes TLR7/8 Agonist Into Phase III With Latest VC Mega-Round
The company is moving its toll-like receptor 7/8 agonist into late-stage development for melanoma as it closes a $350.7m series D venture funding round.
The company is moving its toll-like receptor 7/8 agonist into late-stage development for melanoma as it closes a $350.7m series D venture funding round.